Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The person has given written consent to participate in the trial.
• The person is male and aged 18 or older at the time of signing consent.
• The person has a confirmed diagnosis of prostate cancer (adenocarcinoma), or a clear diagnosis of prostate cancer that has spread to bones or lymph nodes, along with a raised PSA level in the blood.
• The person has a general health and activity level rated at 0, 1, or 2 on a standard medical scale (meaning they are able to carry out some daily activities, even if limited — confirm with trial site).
• The person has previously received at least one course of taxane chemotherapy (a specific type of cancer drug), unless their doctor determined it was medically unsuitable.
• The person has previously been treated with at least one newer type of hormone-blocking drug for prostate cancer, such as enzalutamide, abiraterone, apalutamide, or darolutamide.
• The cancer has shown signs of getting worse, based on rising PSA blood test results, growth of measurable tumours, or new spots appearing on a bone scan.
• The person has either had surgical removal of the testicles or is currently receiving hormone-lowering injections to keep testosterone very low.
• The person's testosterone level in the blood is at or below a very low threshold (≤ 1.75 nmol/L or ≤ 50 ng/dL).
• A special type of scan (PSMA PET/CT) shows that the cancer strongly absorbs a PSMA-targeted tracer, meeting specific minimum uptake levels at sites of disease (confirm exact scan requirements with trial site).
• The person is expected to live for at least 6 months.
• The person has adequate blood counts, liver function, and kidney function, meeting specific minimum levels set by the trial (confirm exact required values with trial site).
• Sexually active participants are willing to use an appropriate barrier method of contraception.
• The person is willing and able to follow all trial requirements, including attending all assessments and completing all treatments.
• At least 3 weeks have passed since any surgery or radiotherapy before joining the trial.

Who may not be able to join:

• The person has previously been treated with any radioactive substance targeting cancer, such as PSMA-targeted radioligand therapy, radium-223, strontium-89, or samarium-153.
• A PET scan shows areas of cancer that do not respond to the PSMA tracer but do show up on a different type of scan (FDG-PET), suggesting the cancer may not respond to this treatment.
• The person has been diagnosed with another cancer (other than certain low-risk skin cancers) within the past 2 years that is likely to return within 24 months.
• The person has cancer that has spread to the brain and is causing symptoms, or cancer affecting the lining around the brain and spinal cord.
• The person has, or is at risk of developing, spinal cord compression that is causing symptoms and has not been treated and stabilised for more than 4 weeks.
• The person has another serious illness or severe infection that could make it unsafe to participate in the trial procedures.

Important: Always verify eligibility with the trial site directly before applying.